Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy

Jeremy C. McMurray, Curtis S. Pacheco, Brandon J. Schornack, Xiaoping Sun, Janet A. Brunader, Alexis E. Scott, Juan S. Ariza, Chung-Ting J. Kou, Ryan C. Costantino, Luke M. Pittman, Karla E. Adams, Aubri M. Waters, Eric M. Pryor, Jonathan J. Lyons, Dean D. Metcalfe, Irina Maric, Nathan A. Boggs

Blood (2024) 144 (4): 408–419.

https://doi.org/10.1182/blood.2023023347

Published: 2024

Includes: Supplemental data

Journal Articles

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

Christopher Trindade, MD, Xiaoping Sun, PhD, Dragan Maric, PhD, Chunjie Jiang, Christopher S. Hourigan, DPhil FACP FRCP, Dean D. Metcalfe, MD, Amy Klion, MD, Irina Maric, MD MSci

Blood (2018) 132 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2018-99-118797

Published: 2018

Journal Articles

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

Peter Valent, Cem Akin, Dean D. Metcalfe

Blood (2017) 129 (11): 1420–1427.

https://doi.org/10.1182/blood-2016-09-731893

Published: 2017

Includes: Supplemental data

Journal Articles

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

Blood (2013) 121 (13): 2393–2401.

https://doi.org/10.1182/blood-2012-09-458521

Published: 2013

Includes: Supplemental data

Journal Articles

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

Daniel Smrž, Mi-Sun Kim, Shuling Zhang, Beverly A. Mock, Šárka Smržová, Wendy DuBois, Olga Simakova, Irina Maric, Todd M. Wilson, Dean D. Metcalfe, Alasdair M. Gilfillan

Blood (2011) 118 (26): 6803–6813.

https://doi.org/10.1182/blood-2011-06-359984

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation

Geethani Bandara, PhD, Yun Bai, MS, Eunice Ching Chan, PhD, Irina Maric, MD, Olga Simakova, PhD, Scott C. Wise, MS, Daniel Flynn, PhD, Dean D Metcalfe, MD, Alasdair M Gilfillan, PhD, Todd M Wilson, DO

Blood (2011) 118 (21): 1740.

https://doi.org/10.1182/blood.V118.21.1740.1740

Published: 2011

Journal Articles

KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation

Youl-Nam Lee, Stephanie Brandal, Pierre Noel, Erik Wentzel, Joshua T. Mendell, Michael A. McDevitt, Reuben Kapur, Melody Carter, Dean D. Metcalfe, Clifford M. Takemoto

Blood (2011) 117 (13): 3629–3640.

https://doi.org/10.1182/blood-2010-07-293548

Published: 2011

Includes: Supplemental data

Journal Articles

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

Peter Valent, Michel Arock, Cem Akin, Wolfgang R. Sperr, Andreas Reiter, Karl Sotlar, Karin Hartmann, Tracy I. George, Knut Brockow, Hanneke C. Kluin-Nelemans, Jason Gotlib, Dean D. Metcalfe, Hans-Peter Horny

Blood (2010) 116 (5): 850–851.

https://doi.org/10.1182/blood-2010-05-285270

Published: 2010

Journal Articles

Mast cells and mastocytosis

Dean D. Metcalfe

Blood (2008) 112 (4): 946–956.

https://doi.org/10.1182/blood-2007-11-078097

Published: 2008

Journal Articles

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis

Cem Akin, Linda M. Scott, Can N. Kocabas, Nataliya Kushnir-Sukhov, Erica Brittain, Pierre Noel, Dean D. Metcalfe

Blood (2007) 110 (7): 2331–2333.

https://doi.org/10.1182/blood-2006-06-028100

Published: 2007

Journal Articles

Human tissue mast cells are an inducible reservoir of persistent HIV infection

J. Bruce Sundstrom, Jane E. Ellis, Gregory A. Hair, Arnold S. Kirshenbaum, Dean D. Metcalfe, Hong Yi, Adriana C. Cardona, Michael K. Lindsay, Aftab A. Ansari

Blood (2007) 109 (12): 5293–5300.

https://doi.org/10.1182/blood-2006-11-058438

Published: 2007

Journal Articles

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Todd M. Wilson, Irina Maric, Amy D. Klion, Cem Akin, Melody Carter, Weiming Fu, Jennifer Stoddard, Linda Scott, Arnold Kirshenbaum, Michael Fay, Thomas B. Nutman, Pierre Noel, Dean D. Metcalfe, Jamie Robyn

Blood (2006) 108 (11): 2683.

https://doi.org/10.1182/blood.V108.11.2683.2683

Published: 2006

Journal Articles

Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood.

Irina Maric, MD, Jamie Robyn, M.D., Ph.D., Weiming Fu, M.D., Jennifer Stoddard, Dean D. Metcalfe, M.D., Pierre Noel, M.D.

Blood (2006) 108 (11): 3596.

https://doi.org/10.1182/blood.V108.11.3596.3596

Published: 2006

Journal Articles

Kit Signaling Regulates Mitf Expression in Mastocytosis.

Youl-Nam Lee, PhD, Pierre Noel, M.D., Amir Shahlaee, M.D., Melody Carter, M.D., Reuben Kapur, Ph.D., Alan Wayne, M.D., Dean D. Metcalfe, M.D., Clifford Takemoto, M.D.

Blood (2006) 108 (11): 3601.

https://doi.org/10.1182/blood.V108.11.3601.3601

Published: 2006

Journal Articles

High-resolution tracking of cell division demonstrates differential effects of T H 1 and T H 2 cytokines on SCF-dependent human mast cell production in vitro:correlation with apoptosis and Kit expression

Marianna Kulka, Dean D. Metcalfe

Blood (2005) 105 (2): 592–599.

https://doi.org/10.1182/blood-2004-07-2838

Published: 2005

Journal Articles

Kit and FcϵRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells

Thomas R. Hundley, Alasdair M. Gilfillan, Christine Tkaczyk, Marcus V. Andrade, Dean D. Metcalfe, Michael A. Beaven

Blood (2004) 104 (8): 2410–2417.

https://doi.org/10.1182/blood-2004-02-0631

Published: 2004

Journal Articles

NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcϵRI aggregation

Christine Tkaczyk, Vaclav Horejsi, Shoko Iwaki, Petr Draber, Lawrence E. Samelson, Anne B. Satterthwaite, Dong-Ho Nahm, Dean D. Metcalfe, Alasdair M. Gilfillan

Blood (2004) 104 (1): 207–214.

https://doi.org/10.1182/blood-2003-08-2769

Published: 2004

Journal Articles

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

Cem Akin, Gerard Fumo, Akif S. Yavuz, Peter E. Lipsky, Len Neckers, Dean D. Metcalfe

Blood (2004) 103 (8): 3222–3225.

https://doi.org/10.1182/blood-2003-11-3816

Published: 2004

Journal Articles

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

Gerard Fumo, Cem Akin, Dean D. Metcalfe, Len Neckers

Blood (2004) 103 (3): 1078–1084.

https://doi.org/10.1182/blood-2003-07-2477

Published: 2004

Journal Articles

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Amy D. Klion, Jamie Robyn, Cem Akin, Pierre Noel, Margaret Brown, Melissa Law, Dean D. Metcalfe, Cynthia Dunbar, Thomas B. Nutman

Blood (2004) 103 (2): 473–478.

https://doi.org/10.1182/blood-2003-08-2798

Published: 2004

NARROW

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy

Immunophenotypic Patterns of Bone Marrow Eosinopoiesis in Patients with Hypereosinophillic Syndrome and Systemic Mastocytosis

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

Targeting the KIT Activating Switch Control Pocket: A Novel Mechanism to Inhibit Mast Cell Activation and KIT D816V Neoplastic Mast Cell Proliferation

KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD)

Mast cells and mastocytosis

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis

Human tissue mast cells are an inducible reservoir of persistent HIV infection

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood.

Kit Signaling Regulates Mitf Expression in Mastocytosis.

High-resolution tracking of cell division demonstrates differential effects of T H 1 and T H 2 cytokines on SCF-dependent human mast cell production in vitro:correlation with apoptosis and Kit expression

Kit and FcϵRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells

NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcϵRI aggregation

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only